Anti-Cancer Drugs : Impact Factor & More
eISSN: 1473-5741pISSN: 0959-4973
Share this on:
Aims and Scope of Anti-Cancer Drugs
Anti-Cancer Drugs is an international medical journal, which aims to promote and encourage research on anti-cancer agents. It was first published in 1990 and it includes reports on clinical and experimental research results, from conventional cytotoxic chemotherapy to hormonal or biological response modalities. The journal has 10 issues per year and the current editor in chief is Mels Sluyser. According to the 2014 Journal Citation Reports, the journal has an impact factor of 1.784, ranking it 164th out of 211 in the category Oncology and 162nd out of 254 in the category Pharmacology & Pharmacy. Less
Key Metrics
CiteScore 
5.2
H-Index
98
Impact Factor
< 5
SJR
Q3Oncology
SNIP
0.52
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Anti-Cancer Drugs
Anti-Cancer Drugs Journal Specifications
| Overview | |
| Publisher | LIPPINCOTT WILLIAMS & WILKINS |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1990 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Anti-Cancer Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Anti-Cancer Drugs
EP4 influences bortezomib resistance in multiple myeloma by modulating endoplasmic reticulum stress via the phosphatidylinositol 3-kinase/protein kinase B pathway.
- 17 Nov 2025
- Anti-cancer drugs
Initial stage analysis of tislelizumab in combination with chemotherapy for patients with advanced HIV-positive non-small-cell lung cancer: a comparative clinical trial.
- 6 Nov 2025
- Anti-cancer drugs
Ubiquitylation-oxaliplatin-related prognosis signature reveals the landscapes of immune responses, cell communication, and therapeutic sensitivity for colorectal cancer.
- 5 Nov 2025
- Anti-cancer drugs
Precision design of an HLA-I-targeted multiepitope vaccine against human papillomavirus 16 oncoproteins E6/E7: integrated immunoinformatic and immunogenicity profiling.
- 5 Nov 2025
- Anti-cancer drugs
A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development.
- 5 Nov 2025
- Anti-cancer drugs
Activation of the caspase-1/gasdermin D pathway via α-linolenic acid-mediated GPR120 signaling induces pyroptosis and suppresses ovarian cancer tumor growth.
- 5 Nov 2025
- Anti-cancer drugs
EP4 influences bortezomib resistance in multiple myeloma by modulating endoplasmic reticulum stress via the phosphatidylinositol 3-kinase/protein kinase B pathway.
- 17 Nov 2025
- Anti-cancer drugs
Initial stage analysis of tislelizumab in combination with chemotherapy for patients with advanced HIV-positive non-small-cell lung cancer: a comparative clinical trial.
- 6 Nov 2025
- Anti-cancer drugs
Ubiquitylation-oxaliplatin-related prognosis signature reveals the landscapes of immune responses, cell communication, and therapeutic sensitivity for colorectal cancer.
- 5 Nov 2025
- Anti-cancer drugs
Precision design of an HLA-I-targeted multiepitope vaccine against human papillomavirus 16 oncoproteins E6/E7: integrated immunoinformatic and immunogenicity profiling.
- 5 Nov 2025
- Anti-cancer drugs
A novel anticancer natural product SP09 selectively targets KRAS-mutant NSCLC through LKB1/AMPK/mTOR modulation: implications for novel therapeutic development.
- 5 Nov 2025
- Anti-cancer drugs
Activation of the caspase-1/gasdermin D pathway via α-linolenic acid-mediated GPR120 signaling induces pyroptosis and suppresses ovarian cancer tumor growth.
- 5 Nov 2025
- Anti-cancer drugs
FAQs on Anti-Cancer Drugs
How long has Anti-Cancer Drugs been actively publishing? 
What is the publishing frequency of Anti-Cancer Drugs?
How many articles did Anti-Cancer Drugs publish last year?
What is the eISSN & pISSN for Anti-Cancer Drugs?
What is Citescore for Anti-Cancer Drugs?
What is the H Index for Anti-Cancer Drugs ?
What is SNIP score for Anti-Cancer Drugs?
What is the SJR for Anti-Cancer Drugs?
Who is the publisher of Anti-Cancer Drugs?
